GANX - Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight | Benzinga
BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (NASDAQ:GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a 2024 Research & Development update on recent in vivo data for GT-02287 along with valuable insights from Key Opinion Leaders.
Event Details
"Beyond Symptomatic Treatment of Parkinson's Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024"
Date: February 22nd, 2024
Time: 11:00 am - 12:00 pm EST
Register for the Event HERE.
Send any questions you'd like answered in our Q&A to ir@gaintherapeutics.com.
Discussion Topics
GBA-associated Parkinson's Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
From biology to classification: understanding Parkinson's Disease.
Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson's Disease and other neurodegenerative diseases.
Speakers
Gain Therapeutics
Matthias Alder - Chief Executive Officer
Joanne Taylor – Senior Vice President, Research
Key Opinion Leaders
Professor Roy Alcalay
- Prof. Alcalay is Chief of the Movement Disorders Division at Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. He also holds an associate professorship in clinical neurology at Columbia University. His research focuses on biomarkers and genetics in Parkinson's Disease. He is a member of The Michael J. Fox Foundation-funded Parkinson's Progression Markers Initiative (PPMI) executive steering committee, and the PI of the Parkinson's Foundation-funded PD GENEration study.
Professor Tiago Fleming Outeiro
- Prof. Outeiro is Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen in Germany. He is also Professor at Newcastle University. His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson's, Huntington's, and Alzheimer's disease. He is Chair of the Task Force on the Biological Definition of Parkinson's Disease of Internation Parkinson and Movement Disorder Society.
About GT-02287
Gain Therapeutics' lead drug candidate, GT-02287, currently being evaluated in a Phase 1 clinical trial, has the potential to be a disease-modifying treatment of GBA1 Parkinson's disease (GBA1-PD) and other neurodegenerative diseases. The orally administered small molecule that crosses the blood-brain barrier is an allosteric protein modulator that restores the function of the lysosomal protein glucocerebrosidase (GCase). In GBA1-PD patients, this enzyme becomes misfolded and ...